<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959399</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-PK26</org_study_id>
    <nct_id>NCT01959399</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Sequence Drug Interaction Study to Evaluate the Effect of Multiple-Dose ASP015K on the Pharmacokinetics of Rosuvastatin in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will be to assess the effect of multiple-doses of ASP015K on the
      pharmacokinetics of rosuvastatin in healthy adult male and female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameter for rosuvastatin: AUClast</measure>
    <time_frame>Days 1 and 10</time_frame>
    <description>Area under the curve to the last measurable time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter for rosuvastatin: AUCinf</measure>
    <time_frame>Days 1 and 10</time_frame>
    <description>Area under the curve to the infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter for rosuvastatin: Cmax</measure>
    <time_frame>Days 1 and 10</time_frame>
    <description>Maximum Concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of pharmacokinetic parameters for rosuvastatin: time after dosing when Cmax occurs (tmax), apparent-terminal elimination half-life (t1/2), apparent volume of distribution (Vz/F), apparent plasma clearance (CL/F)</measure>
    <time_frame>Days 1 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of PK parameters for ASP015K: Area under the curve in the dosing interval (AUCtau), Maximum Concentration (Cmax), time after dosing when Cmax occurs (tmax), apparent volume of distribution (Vz/F), apparent plasma clearance at steady (CLss/F)</measure>
    <time_frame>Days 9 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter for ASP015K: Ctrough</measure>
    <time_frame>Days 7-10</time_frame>
    <description>Plasma concentration immediately before the next administration of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter for ASP015K metabolites: Ctrough</measure>
    <time_frame>Days 7-10</time_frame>
    <description>Plasma concentration immediately before the next administration of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of pharmacokinetic parameters for ASP015K metabolites: Area under the curve in the dosing interval (AUCtau), Maximum Concentration (Cmax), time after dosing when Cmax occurs (tmax)</measure>
    <time_frame>Days 9 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed adverse events, clinical laboratory evaluations, 12-lead ECG measurements, physical examination and vital sign measurements</measure>
    <time_frame>Day 1-14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Pharmacokinetics of ASP015K</condition>
  <arm_group>
    <arm_group_label>ASP015K + rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP015K</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>ASP015K + rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>ASP015K + rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a Body Mass Index (BMI) range of 18.5-32.0 kg/m2, inclusive, and must
             weigh at least 50 kg at screening.

          -  Asian subject must be first generation Japanese born in Japan with both parents and
             four grandparents of Japanese descent and have resided outside of Japan for 5 years or
             less, or first generation Chinese born in China with both parents and four
             grandparents of Chinese descent and have resided outside of China for 5 years or less,
             or first generation Korean born in Korea with both parents and four grandparents of
             Korean descent and have resided outside of Korea for 5 years or less.

          -  Non-Asian subject is self-reported as White, Black or African American, and Hispanic
             or Latino.

          -  Female subject must be of non-childbearing potential (i.e., post-menopausal [defined
             as at least 1 year without menses] prior to screening or documented surgically sterile
             or status post hysterectomy [at least 1 month prior to screening]).

          -  Female subject must have a negative pregnancy test at screening and day -1.

          -  Female subject must not donate ova starting at screening and throughout the study
             period, and for 90 days after the final study drug administration.

          -  Male subject and his female spouse/partner who is of childbearing potential must be
             using highly effective contraception consisting of two forms of birth control (one of
             which must be a barrier method) starting at screening and continue throughout the
             study period and for 90 days after final study drug administration.

          -  Male subject must not donate sperm from screening and throughout the study period and
             for 90 days after final study drug administration.

          -  Subject agrees not to participate in another investigational study while on treatment.

          -  Subject must be capable of swallowing multiple tablets.

        Exclusion Criteria:

          -  Female subject who has been pregnant within 6 months before screening assessment or
             breast feeding within 3 months before screening.

          -  Subject has a known or suspected hypersensitivity to rosuvastatin, ASP015K, or any
             components of the formulations used.

          -  Subject has had a previous intolerance or adverse reaction to a statin therapy.

          -  Subject has any clinically significant history of allergic conditions (including drug
             allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated,
             asymptomatic, seasonal allergies at time of dosing).

          -  Subject has any history or evidence of any clinically significant cardiovascular,
             gastro intestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic,
             urologic, pulmonary neurologic, dermatologic, psychiatric, renal, and/or other major
             disease or malignancy, as judged by the Investigator or designee.

          -  Subject has/had febrile illness or symptomatic, viral, bacterial (including upper
             respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to day
             -1.

          -  Subject has a mean pulse &lt; 40 or &gt; 90 beats per minute (bpm); mean systolic blood
             pressure (SBP) &gt; 140 mmHg; mean diastolic blood pressure (DBP) &gt; 90 mmHg (measurements
             taken in triplicate after subject has been resting in sitting position for at least 5
             minutes at screening and day -1.

          -  Subject has used any prescribed or non-prescribed drugs (including vitamins, natural
             and herbal remedies, e.g. St. John's Wort) in the 2 weeks prior to study drug
             administration, with the exception of hormone replacement therapy (HRT) and
             intermittent acetaminophen (to a maximum of 2 g/day).

          -  Subject has smoked or has used tobacco-containing products and nicotine or nicotine
             containing products in the past 6 months prior to screening.

          -  Subject has a history of consuming more than 14 units of alcoholic beverages per week
             within 6 months prior to screening or has a history of alcoholism or
             drug/chemical/substance abuse within past 2 years prior to screening (Note: one unit =
             12 ounces of beer, 4 ounces of wine or 1 ounce of spirits).

          -  Subject has a positive test for alcohol, drugs of abuse, or cotinine at screening or
             day -1.

          -  Subject has used any inducer of liver metabolism (e.g. barbiturates, rifampin) in the
             3 months prior to day -1.

          -  Subject has had any significant blood loss, donated one unit (450 mL) of blood or
             more, or received a transfusion of any blood or blood products within 60 days or
             donated plasma within 7 days prior to clinic check-in on day -1.

          -  Subject has a positive serology test for hepatitis B surface antigen (HBsAg) (total),
             anti hepatitis A virus (Ig M), anti-hepatitis C virus, anti-hepatitis B core, or anti
             HIV type 1 or type 2 at screening.

          -  Subject has participated in any interventional clinical study or has been treated with
             any investigational drugs within 30 days or 5 half-lives of the drug, whichever is
             longer, prior to screening.

          -  Subject has a positive tuberculosis (TB) skin test, Quantiferon Gold test or T-SPOTÂ®
             test at screening.

          -  Subject has received any vaccine within 60 days prior to study drug administration.

          -  Subject has had major gastrointestinal surgery or has a medical condition which may
             inhibit the absorption and/or metabolism of study drug.

          -  Subject anticipates an inability to abstain from xanthine (e.g., caffeine),
             grapefruit, Seville blood oranges (including marmalade), star fruit, or any products
             containing these items from 72 hours prior to day -1 and throughout the duration of
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL - Early Phase Unit</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>October 8, 2013</last_update_submitted>
  <last_update_submitted_qc>October 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP015K</keyword>
  <keyword>healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

